Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials

Venous thromboembolism (VTE) is highly prevalent in patients with cancer. Non-vitamin K antagonist oral anticoagulants (NOACs), directly targeting the enzymatic activity of thrombin or factor Xa, have been shown to be as effective as and safer than traditional anticoagulation for VTE prophylaxis in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yi-Dan Yan, Chi Zhang, Long Shen, Ying-Jie Su, Xiao-Yan Liu, Li-Wei Wang, Zhi-Chun Gu
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018-06-01
Colecção:Frontiers in Pharmacology
Assuntos:
non-vitamin K antagonist oral anticoagulants
dabigatran
rivaroxaban
apixaban
edoxaban
cancer
Acesso em linha:https://www.frontiersin.org/article/10.3389/fphar.2018.00575/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados